11.62

0.26% 0.03

After Hours: 11.50 -0.12 -1.03%

CorMedix Inc (CRMD)

Overview News Price History Option Chain Discussions Forecast Stock Split

CorMedix Inc stock is traded at $11.62, with a volume of 1.08M. It is up +0.26% in the last 24 hours and down -7.85% over the past month. CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Previous Close:

$11.59

Open:

$11.63

24h Volume:

1.08M

Relative Volume:

0.55

Market Cap:

$989.56M

Revenue:

$65,400

Net Income/Loss:

$-46.34M

P/E Ratio:

-12.63

EPS:

-0.92

Net Cash Flow:

$-38.74M

1W Performance:

-22.33%

1M Performance:

-7.85%

6M Performance:

+42.05%

1Y Performance:

+181.36%

1-Day Range:

$11.34

$11.73

1-Week Range:

$11.34

$12.98

52-Week Range:

$3.61

$17.43

CorMedix Inc Stock (CRMD) Company Profile

Name

CorMedix Inc

Sector

Healthcare (1160)

Industry

Biotechnology (651)

Phone

908-517-9500

Address

400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ

Employee

Twitter

Next Earnings Date

2025-03-25

Latest SEC Filings

CRMD's Discussions on Twitter

Compare CRMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRMD CorMedix Inc	11.62	989.56M	65,400	-46.34M	-38.74M	-0.92
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Initiated	Leerink Partners	Outperform
Jan-13-25	Initiated	D. Boral Capital	Buy
Aug-26-24	Initiated	Rodman & Renshaw	Buy
Aug-10-23	Initiated	RBC Capital Mkts	Outperform
Feb-17-21	Initiated	Needham	Buy
Sep-29-20	Initiated	JMP Securities	Mkt Outperform
Sep-21-20	Initiated	Truist	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Mar-26-19	Reiterated	H.C. Wainwright	Buy
Dec-06-18	Initiated	ROTH Capital	Buy
Sep-25-17	Reiterated	H.C. Wainwright	Buy
Aug-10-17	Reiterated	Rodman & Renshaw	Buy
May-05-17	Reiterated	Rodman & Renshaw	Buy
Nov-11-16	Reiterated	FBR & Co.	Outperform
Mar-17-16	Reiterated	FBR Capital	Outperform
Mar-03-16	Initiated	FBR Capital	Outperform
Nov-16-15	Reiterated	ROTH Capital	Neutral
Oct-29-15	Reiterated	ROTH Capital	Neutral
May-06-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-08-14	Reiterated	ROTH Capital	Buy
Oct-03-11	Downgrade	Maxim Group	Buy → Hold

View All

CorMedix Inc Stock (CRMD) Latest News

Jun 18, 2025

Despite shrinking by US$64m in the past week, CorMedix (NASDAQ:CRMD) shareholders are still up 366% over 3 years - simplywall.st

Jun 18, 2025

Jun 13, 2025

CorMedix stock rises after earnings, revenue beat - MSN

Jun 13, 2025

Jun 11, 2025

CorMedix stock soars to 52-week high, hits $15.33 By Investing.com - Investing.com South Africa

Jun 11, 2025

CorMedix stock soars to 52-week high, hits $15.33 - Investing.com Australia

Jun 11, 2025

Jun 09, 2025

Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com

Jun 09, 2025

Jun 07, 2025

Cormedix anticipates Q2 revenue at high end of $23M-$31M range with inpatient growth accelerating - MSN

Jun 07, 2025

Jun 05, 2025

CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth By Investing.com - Investing.com Canada

Jun 05, 2025

CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth - Investing.com Australia

Jun 05, 2025

CorMedix stock rises as Q1 earnings and revenue surpass estimates By Investing.com - Investing.com Nigeria

Jun 05, 2025

CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position - Seeking Alpha

Jun 05, 2025

Jun 04, 2025

CorMedix:Exceeding Expectations (NASDAQ:CRMD) - Seeking Alpha

Jun 04, 2025

May 30, 2025

CorMedix Inc. to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 30, 2025

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference - The Manila Times

May 30, 2025

CorMedix Brings Latest Therapeutic Developments to Jefferies Healthcare Conference 2025 - Stock Titan

May 30, 2025

May 28, 2025

(CRMD) Trading Advice - news.stocktradersdaily.com

May 28, 2025

May 23, 2025